Immuneering (IMRX) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary

Key clinical results and drug profile

• Atebimetinib, a first-in-class Deep Cyclic Inhibitor, showed 64% overall survival at 12 months in first-line pancreatic cancer, nearly double the standard of care benchmark.

• The drug operates via three mechanisms: shrinking tumors, preserving body mass, and minimizing side effects, all contributing to improved survival.

• Disease control rate reached 81%, and 84% of patients maintained or gained weight, with minimal Grade 3+ adverse events.

• Secondary endpoints also showed strong separation from standard of care: progression-free survival of 8.5 months and overall response rate of 39%.

• The drug’s tolerability allows full-dose combination with chemotherapy, with adverse events mainly attributable to the chemotherapy, not atebimetinib.

Clinical development and future plans

• A global, randomized Phase III trial (MAPKeeper 301) is set to begin dosing mid-year, comparing atebimetinib plus modified gemcitabine/nab-paclitaxel to standard of care.

• The trial is fully funded, aligned with FDA and EMA, and will enroll 510 patients with overall survival as the primary endpoint.

• Expanded cohort data (over 50 patients) will be reported in the first half of 2026, with trends consistent with initial results.

• Atebimetinib is also being studied in combination with Libtayo for lung cancer, with first patient dosing expected in the second half of the year.

• The company holds a composition of matter patent for atebimetinib, granting exclusivity until at least 2042.

Differentiation and market positioning

• Atebimetinib’s triple mechanism distinguishes it from RAS and legacy MEK inhibitors, which lack efficacy in RAF-driven tumors, body mass preservation, or minimal side effects.

• Cross-trial comparisons show atebimetinib outperforms all three standard of care regimens (gem/nab, FOLFIRINOX, NALIRIFOX) in overall survival, even in an older patient population.

• Key opinion leaders (KOLs) are excited by the drug’s ability to improve survival through multiple mechanisms, enhancing both survival and quality of life.

• Investigators and sites have shown high enthusiasm, with strong demand for patient enrollment and positive feedback on the drug’s profile.

• The company emphasizes transparency, having released both survival data and baseline demographics, and calls for similar disclosure from competitors.